Pharmacokinetic Study of Cisplatin and Infusional Etoposide Phosphate in Advanced Breast Cancer with Correlation of Response to Topoisomerase IIα Expression

Clinical Cancer Research

Volumn 9, Issue 13, 2003, Pages 4682-4688

  Braybrooke, Jeremy P ^a   Levitt, Nicola C ^a   Joel, Simon ^b   Davis, Theresa ^c   Madhusudan, Srinivasan ^a   Turley, Helen ^a   Wilner, Sue ^a   Harris, Adrian L ^a   Talbot, Denis C ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) ALPHA; ETOPOFOS; FLUOROURACIL; ISOENZYME; METHOTREXATE; METOCLOPRAMIDE; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG INFUSION; DRUG RESPONSE; FATIGUE; GENE EXPRESSION; HEARING IMPAIRMENT; HUMAN; IMMUNOHISTOCHEMISTRY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OTOTOXICITY; PRIORITY JOURNAL; SENSORY NEUROPATHY; SEPSIS; STEADY STATE; THROMBOCYTOPENIA; TUMOR GROWTH; VEIN THROMBOSIS; VOMITING;

ADULT; AGED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CISPLATIN; COHORT STUDIES; DISEASE PROGRESSION; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; ETOPOSIDE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPHOSPHORUS COMPOUNDS; RECEPTORS, ESTROGEN; TIME FACTORS;

EID: 0142250391     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Kellner, U., Sehested, M., Jensen, P. B., Gieseler, F., and Rudolph, P. Culprit and victim - DNA topoisomerase II. Lancet Oncol., 3: 235-243, 2002.
2. Joel, S. P., and Slevin, M. L. Schedule-dependent topoisomerase II-inhibiting drugs. Cancer Chemother. Pharmacol., 34: S84-S88, 1994.
3. Smyth, R. D., Pfeffer, M., Scalzo, A., and Comis, R. L. Bioavailability and pharmacokinetics of etoposide (VP-16). Semin. Oncol., 12: 48-51, 1985.
4. D'Incalci, M., Rossi, C., Zucchetti, M., Urso, R., Cavalli, F., Mangioni, C., Willems, Y., and Sessa, C. Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cancer Res., 46: 2566-2571, 1986.
5. Clark, P. I., Slevin, M. L., Joel, S. P., Osborne, R. J., Talbot, D. C., Johnson, P. W., Reznek, R., Masud, T., Gregory, W., and Wrigley, P. F. A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. J. Clin. Oncol., 12: 1427-1435, 1994.
6. Joel, S. P., Ellis, P., O'Byrne, K., Papamichael, D., Hall, M., Penson, R., Nicholls, S., O'Donnell, C., Constantinou, A., Woodhull, J., Nicholson, M., Smith, I., Talbot, D., and Slevin, M. Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer. J. Clin. Oncol., 14: 1903-1912, 1996.
7. Slevin, M. L. The clinical pharmacology of etoposide. Cancer (Phila.), 67: 319-329, 1991.
8. Millward, M. J., Newell, D. R., Yuen, K., Matthews, J. P., Balmanno, K., Charlton, C. J., Gumbrell, L., Lind, M. J., Chapman, F., Proctor, M., et al. Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer. Cancer Chemother. Pharmacol., 37: 161-167, 1995.
9. Joel, S. P., Clark, P. I., Heap, L., Webster, L., Robbins, S., Craft, H., and Slevin, M. L. Pharmacological attempts to improve the bioavailability of oral etoposide. Cancer Chemother. Pharmacol., 37: 125-133, 1995.
10. Schacter, L. P., Igwemezie, L. N., Seyedsadr, M., Morgenthien, E., Randolph, J., Albert, E., and Santabarbara, P. Clinical and pharmacokinetic overview of parenteral etoposide phosphate. Cancer Chemother. Pharmacol., 34: S58-S63, 1994.
11. Budman, D. R. Early studies of etoposide phosphate, a water-soluble prodrug. Semin. Oncol., 23: 8-14, 1996.
12. Martin, M., Lluch, A., Casado, A., Santabarbara, P., Adrover, E., Valverde, J. J., Lopez-Martin, J. A., Rodriguez-Lescure, A., Azagra, P., Garcia-Conde, J., et al. Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer. J. Clin. Oncol., 12: 986-991, 1994.
13. Palombo, H., Estape, J., Vinolas, N., Grau, J. J., Mane, J. M., Daniels, M., and Mellado, B. Chronic oral etoposide in advanced breast cancer. Cancer Chemother. Pharmacol., 33: 527-529, 1994.
14. Atienza, D. M., Vogel, C. L., Trock, B., and Swain, S. M. Phase II study of oral etoposide for patients with advanced breast cancer. Cancer (Phila.), 76: 2485-2490, 1995.
15. Bontenbal, M., Planting, A. S., Verweij, J., de Wit, R., Kruit, W. H., Stoter, G., and Klijn, J. G. Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancer. Breast Cancer Res. Treat., 34: 185-189, 1995.
16. Neskovic-Konstantinovic, Z. B., Bosnjak, S. M., Radulovic, S. S., and Mitrovic, L. B. Daily oral etoposide in metastatic breast cancer. Anticancer Drugs, 7: 543-547, 1996.
17. Pusztai, L., Walters, R. S., Valero, V., Theriault, R. L., and Hortobagyi, G. N. Daily oral etoposide in patients with heavily pretreated metastatic breast cancer. Am. J. Clin. Oncol., 21: 442-446, 1998.
18. Cox, E. B., Burton, G. V., Olsen, G. A., and Vugrin, D. Cisplatin and etoposide: an effective treatment for refractory breast carcinoma. Am. J. Clin. Oncol., 12: 53-56, 1989.
19. Cocconi, G., Bisagni, G., Bacchi, M., Boni, C., Bartolucci, R., Ceci, G., Colozza, M. A., De Lisi, V., Lottici, R., Mosconi, A. M., et al. Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J. Clin. Oncol., 9: 664-669, 1991.
20. Lluch, A., Azagra, P., Cervantes, A., Munoz, M., Alberola, V., Santabarbara, P., and Garcia-Conde, J. Phase II trial of cisplatin and etoposide as first-line therapy in metastatic breast carcinoma. Oncology, 51: 352-355, 1994.
21. Remick, S. C., Chmura, M., Bromberg, C., Sporn, J., Healey, B., Hilstro, J., DeConti, R. C., Horton, J., Ruckdeschel, J. C., and Harper, G. R. Concurrent 72-hour continuous infusion of etoposide and cisplatin in metastatic breast cancer. Am. J. Clin. Oncol., 19: 125-131, 1996.
22. Fried, G., Stein, M. E., and Haim, N. Clinical activity of cisplatin and prolonged oral administration of etoposide in previously treated, anthracycline-resistant, metastatic breast cancer patients: a phase II study. Med. Pediatr. Oncol., 34: 10-13, 2000.
23. Krook, J. E., Loprinzi, C. L., Schaid, D. J., Kardinal, C. G., Mailliard, J. A., Pfeifle, D. M., Ellison, N. M., Reuter, N. F., and Nelimark, R. A. Evaluation of the continuous infusion of etoposide plus cisplatin in metastatic breast cancer. A collaborative North Central Cancer Treatment Group/Mayo Clinic phase II study. Cancer (Phila.), 65: 418-421, 1990.
24. Joel, S. P., Shah, R., Clark, P. I., and Slevin, M. L. Predicting etoposide toxicity: relationship to organ function and protein binding. J. Clin. Oncol., 14: 257-267, 1996.
25. Harvey, V. J., Joel, S. P., Johnston, A., and Slevin, M. L. High-performance liquid chromatography of etoposide in plasma and urine. J. Chromatogr., 339: 419-423, 1985.
26. Joel, S., O'Byrne, K., Penson, R., Papamichael, D., Higgins, A., Robertshaw, H., Rudd, R., Talbot, D., and Slevin, M. A randomised, concentration-controlled, comparison of standard (5-day) vs. prolonged (15-day) infusions of etoposide phosphate in small-cell lung cancer. Ann. Oncol., 9: 1205-1211, 1998.
27. Miller, A. B., Hoogstraten, B., Staquet, M., and Winkler, A. Reporting results of cancer treatment. Cancer (Phila.), 47: 207-214, 1981.
28. National Cancer Institute Guidelines for the reporting of adverse events. Bethesda, MD: Division of Cancer Treatment, National Cancer Institute, 1988.
29. Turley, H., Comley, M., Houlbrook, S., Nozaki, N., Kikuchi, A., Hickson, I. D., Gatter, K., and Harris, A. L. The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues. Br. J. Cancer, 75: 1340-1346, 1997.
30. Gehan, A. The determination of the number of patients required in a preliminary and a follow up trial of a new chemotherapeutic agent. J. Chronic Dis., 13: 346-353, 1961.
31. Gasparini, G., Caffo, O., Barni, S., Frontini, L., Testolin, A., Guglielmi, R. B., and Ambrosini, G. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. J. Clin. Oncol., 12: 2094-2101, 1994.
32. Twelves, C. J., Dobbs, N. A., Curnow, A., Coleman, R. E., Stewart, A. L., Tyrrell, C. J., Canney, P., and Rubens, R. D. A phase II, multicentre, UK study of vinorelbine in advanced breast cancer. Br. J. Cancer, 70: 990-993, 1994.
33. Blum, J. L., Dieras, V., Lo Russo, P. M., Horton, J., Rutman, O., Buzdar, A., and Osterwalder, B. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer (Phila.), 92: 1759-1768, 2001.
34. Houlbrook, S., Harris, A. L., Carmichael, J., and Stratford, I. J. Relationship between topoisomerase II levels and resistance to topoisomerase II inhibitors in lung cancer cell lines. Anticancer Res., 16: 1603-1610, 1996.
35. Koshiyama, M., Fujii, H., Kinezaki, M., Morita, Y., Nanno, H., and Yoshida, M. Immunohistochemical expression of topoisomerase IIα (Topo IIα) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas. Anticancer Res., 21: 2925-2932, 2001.
36. Woessner, R. D., Mattern, M. R., Mirabelli, C. K., Johnson, R. K., and Drake, F. H. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ., 2: 209-214, 1991.
37. Smith, K., Houlbrook, S., Greenall, M., Carmichael, J., and Harris, A. L. Topoisomerase II α co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene, 8: 933-938, 1993.
38. Jarvinen, T. A., Kononen, J., Pelto-Huikko, M., and Isola, J. Expression of topoisomerase IIα is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. Am. J. Pathol., 148: 2073-2082, 1996.
39. Jarvinen, T. A., Tanner, M., Rantanen, V., Barlund, M., Borg, A., Grenman, S., and Isola, J. Amplification and deletion of topoisomerase IIα associate with ErbB- 2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am. J. Pathol., 156: 839-847, 2000.